After meeting with lawmakers in January, pharmaceutical leaders have again dropped price increases for the third year in a row. In 2017, only 5.5% of drugs rose by more than 10%, a 5% decrease from 2016 and a 10% decrease from 2015. These decreases have stalled drug prices as leaders look towards innovative cost-cutting strategies. Lowered costs are a direct result of the pharmaceutical industry dedicating itself to lowered costs and full cost transparency. Read the full article here.
